Healthcare / Medical DistributionParis
$5.10
+0.14 (+2.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.1M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
13.4x
↓EV/EBITDA
8.4x
↓ROE
-37.1%
↓Gross Margin
5.3%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-31.3%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $36.2M · net income $-6.1M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36.2M | $36.2M | $34.0M | $54.2M | $111.9M |
| Net Income | $-6.1M | $-6.1M | $13.1M | $-5.9M | $2.3M |
| EBITDA | $878800.00 | $878800.00 | $22.0M | $-4.4M | $4.3M |
| EPS | — | — | 4.60 | -1.97 | 0.63 |
| Gross Margin | 5.3% | 5.3% | 0.5% | 34.6% | 29.9% |
| Operating Margin | 3.6% | 3.6% | -12.5% | -10.0% | 3.3% |
| Net Margin | -16.9% | -16.9% | 38.5% | -10.9% | 2.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.49 | 0.49 | 0.44 | 0.37 | 0.38 |
| Current Ratio | 3.09 | 3.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | — | — | — | $-2.1M | $17.4M |
| Returns | |||||
| ROE | -37.1% | -37.1% | 58.0% | -17.1% | 5.5% |
| Valuation | |||||
| P/E | 13.42 | 13.42 | 1.16 | — | 15.57 |
| EV/EBITDA | 8.44 | 8.44 | 0.29 | — | 4.34 |
| P/B | 0.88 | 0.88 | 0.68 | 0.49 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 6.4% | 6.4% | -37.2% | -51.6% | — |
| EPS Growth | — | — | 333.6% | -412.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.0%
Start / end P/E
n/dx → n/dx
EPS bridge
4.60 → n/d
Residual
+36.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.